$Gilead Sciences(GILD)$ $Gilead Sciences (GILD) +2.17%: Momentum Builds Toward $157 High, $151 Pivot in Focus Latest Close: $150.89 (+3.21) — just 4.1% below the 52-week high of $157.29. Volume surged to 7.84M shares (1.58x ratio), confirming institutional accumulation. Core Market Drivers: Gilead's HIV franchise continues to anchor sentiment following recent FDA approvals (Bixlenvo, Trodelvy). The stock rebounded sharply from early-September biotech sector weakness, with strong Q2 results ($7.80B revenue beat) still underpinning the recovery narrative. Technical Analysis: 📊 RSI-6 at 70.5 signals strong bullish momentum but nears overbought territory; RSI-12 at 64.1 confirms medium-term strength. MACD histogram is negative (-1.85) but rising rapid